Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice

Circulation

Volumn 95, Issue 6, 1997, Pages 1542-1548

  Reckless, Jill ^a   Metcalfe, James C ^a   Grainger, David J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

apolipoproteins; atherosclerosis; lesion; lipids

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HEART INFARCTION; HEART PROTECTION; HYPERCHOLESTEROLEMIA; LIPID DIET; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030953982     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.6.1542     Document Type: Article

References (16)

1. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med. 1995;1:1067-1073.
2. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:313-327.
3. Paigen B, Ishida B, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 1990;10:316-323.
4. Stewart-Philips JL, Lough J. Pathology of atherosclerosis in cholesterol fed, susceptible mice. Atherosclerosis. 1991;90:211-218.
5. MacDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J. 1991;303:435-437.
6. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast-cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993; 85:1398-1406.
7. Dewar JA, Harobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RAB. Long term effects of tamoxifen on blood values in breast cancer. Br Med J. 1992;305:225-226.
8. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, Demets DL. Effect of tamoxifen therapy on lipid and lipoprotein levels in post-menopausal patients with node negative breast cancer. J Natl Cancer Inst. 1990;82:1327-1332.
9. Gordon DJ, Rifkind BM. Current concepts: high density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
10. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A1 transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
11. Grainger DJ, Weissberg P, Metcalfe JC. Tamoxifen decreases the rate of proliferation of rat vascular smooth muscle cells in culture by inducing production of transforming growth factor-β. Biochem J. 1993;294:109-112.
12. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, Mackinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA. Induction of transforming growth factor-β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992;52:4261-4264.
13. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KEP, Danielpour D, Ebbs SR, Sporn MB, Baum M. Anti-estrogens induce the secretion of active transforming growth factor-β from human fetal fibroblasts. Br J Cancer. 1990;62:405-409.
14. Grainger DJ, Metcalfe JC. A pivotal role for TGF-β in atherogenesis. Biol Rev. 1995;70:571-596.
15. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein (a) mice. Nature. 1994;370:460-462.
16. 15a. Lawn RM, Pearl AD, Konz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996; 271:31367-31371.